EXTEND, Phase 2 Trial Evaluating the Safety and Efficacy of Exercise Training in Men with Hormone Naïve Prostate Cancer - Mike Harrison

October 29, 2018

(Length of interview: 16 min)

Mike Harrison and Chuck Ryan dialogue on the specifics of the EXTEND trial. This is a phase 2 trial evaluating the safety and efficacy of exercise training in men receiving enzalutamide plus conventional ADT for hormone naïve prostate cancer. The discussion ensues to the value of exercise in this patient population and some of the nuances in managing patients in this type of trial.

Michael Roger Harrison, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute

Charles J. Ryan, MD

email news signup